On September 14, 2021 i2020, an accelerator program backed by the San Diego-based venture company Torrey Pines Investment, reported two new start-up investments together with OrbiMed Advisors (Press release, i2020 Accelerator, SEP 14, 2021, View Source [SID1234587795]). The start-up proceeds will finance new oncology-focused companies: Gwynant Therapeutics and Celyn Therapeutics. The companies will use the proceeds to bring proprietary small molecule products to the clinic targeting cancer. With this new financing, the partners continue to build a robust innovative asset pipeline focused on breakthrough drug targets. The new investment from i2020 and OrbiMed brings the total funding for 9 companies in the Loch platform to over $68.5 million. The Loch platform aims to rationally design and develop novel targeted treatments for cancer, immunological and neurodegenerative diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In connection with the financing, Carl Gordon and Iain Dukes from OrbiMed, Nikolay Savchuk from Torrey Pines Investment and Augustine Lawlor from Health Care Ventures have joined the Boards of Gwynant and Celyn Therapeutics.

The Loch platform and its programs are supported by the AI and computer aided drug design of Molsoft LLC and ChemDiv Inc., San Diego, CA, as well as other research partners from i2020 Accelerator’s global network.